Figure 3 | Scientific Reports

Figure 3

From: Regulation of cytokine and chemokine expression by histone lysine methyltransferase MLL1 in rheumatoid arthritis synovial fibroblasts

Figure 3

Reduction in H3K4me3 and mRNA levels of cytokine and chemokine genes in RASFs following treatment with the WD repeat domain 5 (WDR5)/MLL1 inhibitor MM-102. (A) H3K4me3 levels of the CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CXCL12 genes in RASFs treated with or without the treatment of 300 pM MM-102 for 72 h, as determined by quantitative ChIP-PCR (n = 8 RA patients). (B) CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CXCL12 mRNA levels in RASFs treated with or without the treatment of 300 pM MM-102 for 72 h, as determined by quantitative RT-PCR (n = 12 RA patients). Bars show the mean ± SEM. Values are expressed as the fold-increase versus the value for RASFs not treated with MM-102. * = P < 0.05; ** = P < 0.01; *** = P < 0.001 by Wilcoxon signed-rank test. See Figs. 1 and 2 for other definitions.

Back to article page